Author: Dino Mustafić

October 3, 2023 0

Exscientia sees maintaining cash runway well into 2026

By Dino Mustafić

Exscientia provided Tuesday an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation, outlinging strategy which will support continued investment into market-leading technology while maintaining cash runway well into 2026.

October 3, 2023 0

Cancer cases and deaths on the rise in the EU

By Dino Mustafić

New cancer cases rose by 2.3 % compared to 2020, to reach 2.74 million in 2022. Similarly, cancer deaths went up by 2.4 % compared to 2020, according to the European Commission’s estimates published in the European Cancer Information System (ECIS).

October 2, 2023 Off

Poolbeg welcomes cancelling patent opposition hearing

By Dino Mustafić

Poolbeg Pharma, a clinical-stage biopharmaceutical company, said last week that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge to the Company’s European patent (Immunomodulator I), has been cancelled.

September 29, 2023 Off

OptiBiotix Health increase gross profit in first six months 2023

By Dino Mustafić

OptiBiotix Health, a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, finished first half of trading with sales of £351k, compared to the year 2022  sales of the same period, of £119k, which is a 195% increase over, the company said in its unaudited results for the six months ended 30 June 2023.